MediWound Ltd. (MDWD) stock: price, suppliers, customers and institutional ownership
Prices via Intrinio. Supplier and customer ties are extracted from SEC filings and carry the sentence they came from. Not investment advice.
Prices via Intrinio. Supplier and customer ties are extracted from SEC filings and carry the sentence they came from. Not investment advice.
MediWound Ltd.
Price, suppliers and customers from SEC filings, institutional ownership and the next report.
Nasdaq · Medicinal Chemicals & Botanical Products
High 13.44 at 3:45 pm ET, low 13.31 at 10:15 am ET.
MediWound Ltd., a biopharmaceutical company, develops, manufactures, and commercializes novel and bio-therapeutic solutions for tissue repair and regeneration. It markets NexoBrid, a biopharmaceutical product for the removal of eschar, a dead or damaged tissue in adults with deep partial- and full-thickness thermal burns to burn centers and hospitals burn units. The company also develops EscharEx, which has completed Phase II clinical trials for the debridement of chronic and other hard-to-heal wounds; MW005, which is in phase I/II for the treatment of low-risk basal cell carcinoma. MediWound Ltd. was founded in 2000 and is headquartered in Yavne, Israel.
No case yet. It builds on the next filing, report or 13F period.
Of the 6 companies MediWound Ltd. moves with most closely, none share its SEC classification.
Measured against 149 trading days of our own closes. Co-movement, not cause.
SIC 2833, Medicinal Chemicals & Botanical Products, from each company's own filings. Largest first.
78 managers report a position worth $85.9M between them, and 12 of them hold 80% of it.
tall tick = annual report · 1 on record
MDWD (MediWound Ltd.) has 0 disclosed suppliers and 0 disclosed customers, strongest disclosure first.
Select a tie for its filing sentence; select again to open the company. Nearer the centre, the more the filings disclose. Extended: satellites hang off single companies, not bundled sectors.